News and Announcements
Cirrus Materials Science to close capital round on Friday 27 September
- Published September 22, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Cirrus Materials Science announces the close of our Pre-Series A capital round for 5 pm on Friday, Sept 27th 2019. We have been delighted with the level of interest so far. During the round, Cirrus has hosted investors from New Zealand and around the world at our Auckland Lab, and provided detailed information via a Virtual Data Room and Meet the CEO investor sessions. We will continue to meet with interested parties on request until 25 September.
The Board of Directors has pre-approved over-subscriptions up to an additional 75,000 shares or $300,000. Key Details are included below and due diligence materials and warranties are available on request.
Please register your interest below for more information.
About Cirrus Materials Science
Cirrus is a New Zealand-based materials design business serving major manufacturing customers in Australasia, US, EU and Asia.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
